神经内分泌瘤肽受体放射性核素治疗新策略的研究进展

Research progress of new peptide receptor radionuclide therapy strategies for neuroendocrine tumor

肽受体放射性核素治疗(PRRT)对于无法手术、系统性治疗效果欠佳但核医学显像证实生长抑素受体过表达的神经内分泌瘤(NET)患者,是一种成功的靶向治疗方法。PRRT可以延长该类患者的生存期,改善患者症状,提高患者生活质量,但治疗后完全缓解者并不多见,仍有较多的患者出现疾病进展,因此,PRRT联合治疗、基于α核素的PRRT等新方案近年来受到关注。笔者结合国内外相关临床研究,对NET的PRRT新策略的研究进展进行综述。

Peptide receptor radionuclide therapy(PRRT)is a successful targeted method for patients with neuroendocrine tumor(NET)who cannot be operated on,with no response to systemic therapy,but with somatostatin receptor overexpression confirmed by nuclear medical imaging.It can prolong survival and improve symptom control and quality of life in these patients.However,the patients with complete response are few,and there are still more patients with disease progression.So,some new approaches,including combination therapy with PRRT andα-nuclide-based PRRT,have attracted much attention recently.Here,this article reviews the research progress of the new PRRT strategies based on both domestic and foreign studies in this field.